Prager N A, Torr-Brown S R, Sobel B E, Abendschein D R
Cardiovascular Division, Washington University, Saint Louis, Missouri.
J Am Coll Cardiol. 1993 Jul;22(1):296-301. doi: 10.1016/0735-1097(93)90847-t.
This study was designed to determine whether maintenance of patency in coronary arteries with high grade stenosis after thrombolysis with tissue-type plasminogen activator requires inhibition of thrombin or platelets, or both.
Activation of both thrombin and platelets has been implicated in delaying coronary recanalization induced with fibrinolytic drugs and in predisposing to reocclusion.
Hirudin (1.5 mg/kg body weight) or aspirin (5 mg/kg), or both, was given conjunctively with tissue-type plasminogen activator in 28 conscious dogs with coronary thrombosis induced by electrical stimulation of the vessel wall in the presence of a previously placed high grade distal stenosis (85 +/- 12% [SEM] area reduction).
Among 22 dogs exhibiting coronary recanalization, hirudin plus aspirin, but neither agent alone, modestly shortened the interval to recanalization (31 +/- 4 min with saline solution, n = 6; 29 +/- 4 min with aspirin, n = 5; 23 +/- 9 min with hirudin, n = 6; 21 +/- 7 min with hirudin+aspirin, n = 5). Reocclusion occurred promptly and persisted in five of six dogs given only saline solution plus tissue-type plasminogen activator, in four of six dogs given hirudin and five of five dogs given aspirin; however, reocclusion was prevented in all five of the dogs given both hirudin and aspirin with tissue-type plasminogen activator (p < 0.05 compared with saline-treated dogs). In dogs given both hirudin and aspirin, the partial thromboplastin time was 2.4 +/- 0.3 times baseline, and the template bleeding time was prolonged only modestly (1.6 +/- 0.3 times baseline).
Thus, the combination of hirudin and aspirin in doses that do not markedly perturb hemostasis prevents early reocclusion after thrombolysis despite the presence of severe stenosis. Accordingly, conjunctive administration of both anti-thrombin and antiplatelet agents appears to be necessary for optimal maintenance of patency after thrombolysis induced in the presence of high grade coronary stenosis.
本研究旨在确定在使用组织型纤溶酶原激活剂进行溶栓后,对于存在高度狭窄的冠状动脉,维持血管通畅是否需要抑制凝血酶或血小板,抑或两者均需抑制。
凝血酶和血小板的激活均与纤维蛋白溶解药物诱导的冠状动脉再通延迟以及再闭塞倾向有关。
在28只清醒犬中,通过电刺激血管壁并预先设置高度远端狭窄(面积减少85±12%[标准误])诱导冠状动脉血栓形成,然后将水蛭素(1.5毫克/千克体重)或阿司匹林(5毫克/千克)或两者与组织型纤溶酶原激活剂联合给药。
在22只出现冠状动脉再通的犬中,水蛭素加阿司匹林可适度缩短再通时间间隔(生理盐水组为31±4分钟,n = 6;阿司匹林组为29±4分钟,n = 5;水蛭素组为23±9分钟,n = 6;水蛭素加阿司匹林组为21±7分钟,n = 5),而单独使用任何一种药物均无此效果。仅给予生理盐水加组织型纤溶酶原激活剂的6只犬中有5只迅速发生再闭塞且持续存在,给予水蛭素的6只犬中有4只、给予阿司匹林的5只犬中有5只发生再闭塞;然而,给予水蛭素和阿司匹林并联合组织型纤溶酶原激活剂的所有5只犬均未发生再闭塞(与生理盐水治疗组犬相比,p < 0.05)。给予水蛭素和阿司匹林的犬中,部分凝血活酶时间为基线的2.4±0.3倍,模板出血时间仅略有延长(为基线的1.6±0.3倍)。
因此,尽管存在严重狭窄,但水蛭素和阿司匹林以不明显干扰止血的剂量联合使用可预防溶栓后的早期再闭塞。因此,对于在存在高度冠状动脉狭窄情况下诱导的溶栓,联合使用抗凝血酶和抗血小板药物似乎对于最佳维持血管通畅是必要的。